Key oncology products, including Tecartus and Yescarta, hold accelerated FDA approval, which is contingent upon successful outcomes in post-market confirmatory trials. This creates a significant regulatory burden and revenue risk, as failure to verify clinical benefit could lead to the approvals being withdrawn.
Filing excerpt
This indication is approved under accelerated approval by FDA, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kcomplianceBurdenGet every 10-K signal for Gilead and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/990da6c9-3f84-4e61-ae0f-9db47ec1a004 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.
{
"signal_id": "990da6c9-3f84-4e61-ae0f-9db47ec1a004",
"signal_type": "sec-10k",
"signal_subtype": "complianceBurden",
"detected_at": "2026-03-03T05:50:03.57+00:00",
"company": {
"name": "Gilead",
"domain": "gilead.com"
},
"data": {
"detail": "Key oncology products, including Tecartus and Yescarta, hold accelerated FDA approval, which is contingent upon successful outcomes in post-market confirmatory trials. This creates a significant regulatory burden and revenue risk, as failure to verify clinical benefit could lead to the approvals being withdrawn.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "Multiple oncology drugs face revenue risk pending confirmatory trials",
"excerpts": "This indication is approved under accelerated approval by FDA, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",
"relevance": 0.7,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm",
"filing_date": "2026-02-24",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "GRC tools needed",
"signal_category": "risk",
"regions_mentioned": [
"U.S."
]
}
}
curl https://signals.autobound.ai/v1/signals/990da6c9-3f84-4e61-ae0f-9db47ec1a004 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.